{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:55:31Z","timestamp":1790744131429,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.07.038","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:45:56Z","timestamp":1786059956000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Large B-Cell Lymphoma after CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-4025","authenticated-orcid":false,"given":"Smith","family":"Kungwankiattichai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4819-0985","authenticated-orcid":false,"given":"Sanjog","family":"Bastola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-9445","authenticated-orcid":false,"given":"Andy I.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-5205","authenticated-orcid":false,"given":"Amrita","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.07.038_bib0001","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-174288","article-title":"Curative potential of axicabtagene ciloleucel (Axi-Cel): an exploratory long-term survival assessment in patients with refractory large B-cell lymphoma from ZUMA-1","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.038_bib0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO-25-00507","article-title":"Five-year analysis of the JULIET trial of tisagenlecleucel in patients with relapsed\/refractory large B-cell lymphoma","volume":"44","author":"Maziarz","year":"2026","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jtct.2026.07.038_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70138","article-title":"Several factors that predict the outcome of large B-cell lymphoma patients who relapse\/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration","volume":"13","author":"S\u00fdkorov\u00e1","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.038_bib0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-025-01771-6","article-title":"Multicenter real-life evaluation of the post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure","volume":"19","author":"Farina","year":"2026","journal-title":"J Hematol Oncol"},{"issue":"27","key":"10.1016\/j.jtct.2026.07.038_bib0005","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.038_bib0006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.038_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.038_bib0008","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.038_bib0009","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-024-01608-8","article-title":"Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment","volume":"17","author":"Iacoboni","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.07.038_bib0010","series-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"},{"issue":"21","key":"10.1016\/j.jtct.2026.07.038_bib0011","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.038_bib0012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"issue":"24","key":"10.1016\/j.jtct.2026.07.038_bib0013","first-page":"2527","article-title":"Post-CAR relapse in DLBCL: a fork in the road","volume":"140","author":"Abramson","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"issue":"24","key":"10.1016\/j.jtct.2026.07.038_bib0014","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.jtct.2026.07.038_bib0015","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.038_bib0016","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.038_bib0017","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.038_bib0018","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.038_bib0019","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3324\/haematol.2023.283480","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.038_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2019.12.012","article-title":"PD-1 imposes qualitative control of cellular transcriptomes in response to T cell activation","volume":"77","author":"Shimizu","year":"2020","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.038_bib0021","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.molcel.2020.02.013","article-title":"PD-1: a driver or passenger of T cell exhaustion?","volume":"77","author":"He","year":"2020","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.jtct.2026.07.038_bib0022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.038_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011768","article-title":"Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance","volume":"13","author":"Ponzo","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.jtct.2026.07.038_bib0024","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"New Engl J Med"},{"issue":"15","key":"10.1016\/j.jtct.2026.07.038_bib0025","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.jtct.2026.07.038_bib0026","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.07.038_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.904497","article-title":"CAR T-cell therapy predictive response markers in diffuse large B-cell lymphoma and therapeutic options after CART19 failure","volume":"13","author":"Caballero","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.038_bib0028","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:59:21Z","timestamp":1790740761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"alternative-id":["S2666636726006019"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.038","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Large B-Cell Lymphoma after CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}